Actinium Pharmaceuticals Presents New Preclinical Data From Its ATNM-400 Across Non-Small Cell Lung Cancer At 39th Annual Congress Of European Association Of Nuclear Medicine
Benzinga Newsdesk 1 month ago
NewsBiotechGeneral
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced new preclinical results
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced new preclinical results demonstrating the broad antitumor potential of ATNM-400 across non-small cell lung cancer (NSCLC), colorectal cancer and ovarian cancer models. The findings were presented in an oral presentation and two e-posters at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM), October 17–21, 2026, in Vienna, Austria.
